DexCom, Inc. (DXCM) Stock
DexCom stock price chart
DXCM stock quote & key statistics
DexCom annual financials
Income statement →| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $4.66B | $836.3M | $2.09 |
| FY2024 | $4.03B | $576.2M | $1.65 |
| FY2023 | $3.62B | $541.5M | $1.51 |
| FY2022 | $2.91B | $341.2M | $0.87 |
| FY2021 | $2.45B | $216.9M | $0.66 |
Fiscal year ending December 31. Source: company filings via EODHD.
About DexCom, Inc.
DexCom, Inc., a leading medical device company, specializes in the innovation, development, and global distribution of continuous glucose monitoring (CGM) systems. These advanced systems are pivotal in managing diabetes, providing real-time glucose data to both individuals with diabetes and healthcare professionals. The flagship product, DexCom G6, represents an integrated CGM system renowned for its accuracy and ease of use, significantly reducing the need for traditional finger stick blood glucose testing. Additionally, DexCom offers Dexcom Real-Time API, facilitating seamless integration of CGM data into digital health applications and devices, and Dexcom Share, a remote monitoring system that enhances diabetes management capabilities.
Looking ahead, DexCom is advancing its product portfolio with the Dexcom G7, the next-generation CGM system aimed at further enhancing user experience and technological capabilities. The company collaborates closely with Verily Life Sciences LLC and Verily Ireland Limited under a strategic agreement to explore innovative blood-based and interstitial glucose monitoring solutions. DexCom markets its products directly to endocrinologists, physicians, and diabetes educators, ensuring widespread adoption and support within the healthcare community.
Established in 1999 and headquartered in San Diego, California, DexCom, Inc. has solidified its position as a pioneer in CGM technology. With a steadfast commitment to improving the lives of individuals with diabetes through continuous innovation, DexCom remains dedicated to advancing the field of glucose monitoring, setting new standards for accuracy, reliability, and patient-centered care.
DexCom stock FAQ
What is the DexCom stock ticker symbol?
DexCom, Inc. trades on the NASDAQ under the ticker symbol DXCM.
What sector and industry is DexCom in?
DexCom, Inc. is classified in the Healthcare sector, Medical Devices industry.
How many employees does DexCom have?
DexCom, Inc. has about 11,000 full-time employees.
What were DexCom's revenue and earnings last fiscal year?
DexCom reported revenue of $4.66B and net income of $836.3M in fiscal 2025, with earnings per share of $2.09. Revenue grew 15.6% from the prior year.
Is DexCom in the Nasdaq-100?
Yes. DexCom, Inc. (DXCM) is a component of the Nasdaq-100 index, which tracks the largest non-financial companies listed on the Nasdaq Stock Market.
Is DexCom in the S&P 500?
Yes. DexCom, Inc. (DXCM) is a component of the S&P 500, the index of 500 leading U.S. companies widely used as a benchmark for the U.S. stock market.
Is DexCom in the Russell 1000?
Yes. DexCom, Inc. (DXCM) is a component of the Russell 1000, which tracks roughly the 1,000 largest U.S. companies.
When did DexCom go public?
DexCom stock began trading on April 14, 2005.